J&J Could File “New Gold Standard” In Anti-TNF Therapy By Late 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
CNTO 148 is in Phase III for RA, ankylosing spondylitis and psoriatic arthritis.
You may also be interested in...
J&J/Centocor Files Golimumab In Three Indications
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
J&J/Centocor Files Golimumab In Three Indications
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
J&J Golimumab BLA Filing Planned For First Half 2008 In Three Indications
Johnson & Johnson’s Centocor unit is positioning the next generation anti-TNF as a once-monthly treatment.